Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 18/20 | 0.82 |
| ▸ | GABRB2 | P47870 | 18/20 | 0.82 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9893977 | 0.92 | GABRA2 (0.80) | GABRA2GABRB2PTGS2 | |
| SCHEMBL1437616 | 0.91 | GABRA2 (0.69) | GABRA2GABRB2PTGS2MDM2 | |
| SCHEMBL9893881 | 0.90 | GABRA2 (0.69) | GABRA2GABRB2PTGS2 | |
| SCHEMBL1437426 | 0.88 | GABRA2 (0.65) | GABRA2GABRB2PTGS2 | |
| SCHEMBL1437420 | 0.86 | GABRA2 (0.62) | GABRA2GABRB2PTGS2 | |
| SCHEMBL1438305 | 0.85 | GABRA2 (1.00) | GABRA2GABRB2PTGS2 | |
| SCHEMBL1437187 | 0.85 | GABRA2 (0.60) | GABRA2GABRB2PTGS2 | |
| SCHEMBL1437529 | 0.83 | GABRA2 (0.67) | GABRA2GABRB2PTGS2 | |
| SCHEMBL4510979 | 0.83 | GABRA2 (1.00) | GABRA2GABRB2PTGS2 | |
| SCHEMBL1437115 | 0.83 | GABRA2 (0.66) | GABRA2GABRB2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470502-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | Novartis AG (CH) | 2012-07-04 | — | — | EP | disclosed |
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
| WO-2011023677-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | GABRA2 4293/4885GABRB2 4278/4885PTGS2 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.